Publication | Closed Access

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial

Metabolic SyndromeDiabetes ManagementUrologyRenal FunctionCardiovascular DiseaseDiabetesChronic Kidney DiseaseType 2Diabetic Kidney DiseaseDiabetes MellitusMedicineEmpa-reg OutcomeNephrology